Podcasts about elderly patients

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Sex Differences in Achieved Diastolic Blood Pressure and Cardiovascular Outcomes in Elderly Patients With Hypertension.

Join us as we explore how Raju Joshi, CCO and Co-founder of Cogensus, is leveraging digital innovation to address loneliness as a critical social determinant of health. Raju brings 30+ years of healthcare expertise to discuss how AI-powered conversations capture patient sentiments, provide valuable clinical context, and preserve personal legacies. This session examines the intersection of technology, social health, and the Surgeon General's focus on loneliness as a public health priority.Combat loneliness through AI-driven conversations that create meaningful connections for vulnerable patientsCapture critical social context missing from traditional clinical data to improve treatment adherence and outcomes for socially isolated patientsIntegrate patient narratives directly into clinical workflows to enable seamless coordination between healthcare providers, caregivers, and patients Raju Joshi, Co-Founder, Chief Clinical Officer, Member Board of Directors, CogensusMegan Antonelli, Chief Executive Officer, HealthIMPACT

Sirolimus-coated Balloon Vs. Drug-eluting Stent in Elderly Patients with Coronary Artery Disease: A Propensity-score Matched Comparison

Dana In The Morning Highlights 4/4A couple of UH Cougars players could be featured in next years NBA GamesRodeo announces dates for next year including a CONCERT ONLY dayA Mom out in Pearland finds her calling helping assist elderly patients who struggle

It may seem counterintuitive, but hospital emergency rooms can be hazardous to the health of elderly patients. An innovative geriatric multidisciplinary ER team at St. Mary's Hospital in Montreal is getting elderly patients discharged quickly and safely, saving them from preventable harms and the hospital millions in preventable admissions.

In recognition of Myeloma Awareness Month 2025, this podcast explores key unmet needs and unanswered questions in myeloma research and... The post Addressing unmet needs in myeloma: early detection, frail/elderly patients, triple-class exposed disease, & more! appeared first on VJHemOnc.

How do you monitor patient health while respecting their privacy? Jamey Edwards, President & Chief Strategy Officer at Cairns Health, shares how their AI-powered assistant, Luna, is addressing this challenge head-on. By using radar instead of cameras, Luna monitors vital signs and behaviors, making it ideal for programs supporting Alzheimer's care and sleep disorders. In this interview, Edwards highlights how Luna simplifies caregiving while encouraging care compliance and reducing stress for families and clinicians alike.Learn more about Cairns Health athttps://www.cairns.ai/ Find more great health IT content athttps://www.healthcareittoday.com/

Show notes at pharmacyjoe.com/episode990. In this episode, I’ll discuss the lowest effective dose of IV or IM haloperidol for elderly hospitalized patients with agitation. The post 990: Lowest Effective Dose of Haloperidol for Agitation in Elderly Patients appeared first on Pharmacy Joe.

Dr. Malcolm Debaun sits down with Dr. Dirk Ter Meulen as he shares an overview of his research entitled, 'Is Cast Treatment Noninferior to Surgery for Elderly Patients with Displaced Intra-Articular Type C Distal Radius Fractures? A Randomized Controlled Noninferiority Trial. Live from the 2024 OTA Annual Meeting. For additional educational resources visit OTA.org  

King and I | S5 E5 | Should Elderly Patients Presented with NSTEMI Undergo Cath and PCI

A Clare MEP insists a primary goal of evaluating the State's response to Covid-19 must be to determine if a decision was made that "some lives are worth more than others". The Cabinet has signed off on the terms of reference of a long-awaited examination of how the Government handled the Covid-19 pandemic, with work expected to begin in the coming weeks. It's been stressed that unlike what took place in the UK, it will be an "evaluation" rather than an inquiry, meaning it won't have statutory powers to compel witnesses or evidence. Scariff-based Independent Member of the European Parliament Michael McNamara, who was the Chair of the Special Committee on Covid-19 Response when it was in place, says if decisions were made that directly led to people's deaths, the facts must be laid bare.

Send us a textDiese Woche geht es im Journal Club um eine Metaanalyse von Pereira et al. aus dem European Journal of Anesthesiology zum Vergleich von Remimazolam mit Propofol zur Allgemeinanästhesie bei älteren Patienten:Pereira EM, Moraes VR, Gaya da Costa M, et al. Remimazolam vs. propofol for general anaesthesia in elderly patients: a meta-analysis with trial sequential analysis. Eur J Anaesthesiol. 2024;41(10):738-748. doi:10.1097/EJA.0000000000002042Im Studio mit dabei: Marlon Rutsch, wissenschaftlicher Mitarbeiter der Klinik für Anästhesiologie am UKHD

Listen to the Q&A between Tom Hansen and Mariana Gaya da Costa as they discuss thee article, “Remimazolam vs. propofol for general anaesthesia in elderly patients: a meta-analysis with trial sequential analysis”, found in the October 2024 issue of the EJA.

Two ages of patients, during two unique points of life's journey — Dr. Jordan and Kevin discuss the differences in diagnosing and treating hearing loss in pediatric and elderly patients. Which does Dr. Jordan prefer? We hope you join us in this very informative episode of the Ask an Audiologist podcast!

News

News

News

Dr. Jacob Fleming and Dr. Douglas Beall discuss the challenges and advancements in treating sacral insufficiency fractures (SIF), the importance of real-world data in evaluating treatment efficacy, and the need to increase awareness of sacral fractures and sacroplasty. --- CHECK OUT OUR SPONSOR Stryker Interventional Spine https://www.strykerivs.com --- SYNPOSIS Dr. Beall emphasizes the underrecognition and undertreatment of sacral insufficiency fractures, pointing out the high mortality and chronic pain rates associated with non-treatment. He urges providers to consider this diagnosis, especially if the patient is describing symptoms of pain with position changes with standing, sitting, and laying, has pubic rami fractures, or reports a history of pelvic radiation. Even with imaging, the diagnosis can remain elusive, since it is not commonly recognized on x-ray and may not show obvious cortical disruption on CT or MRI. We also review the current literature on sacroplasty efficacy in lowering patient-reported pain scores and adverse events associated with treatment versus conservative management. Dr. Beall speaks about the importance of real-world data collection in the form of patient registries and the insight that these resulting studies have on applications of sacroplasty in specific patient populations. --- TIMESTAMPS 00:00 - Introduction 03:01 - Sacral Fractures and Sacroplasty 15:17 - Treatment Options for Sacral Fractures 17:34 - Consequences of Untreated Sacral Fractures 28:32 - Sacroplasty Registry and Current Research 38:08 - Imaging Modalities: CT vs. Fluoroscopy 40:49 - Complications of Sacroplasty: Extravasation 43:21 - Bone Quality and Fracture Healing 45:42 - Growing Awareness of Sacral Fractures and Treatment Options --- RESOURCES Spontaneous osteoporotic fracture of the sacrum. An unrecognized syndrome of the elderly (Lourie, 1982): https://pubmed.ncbi.nlm.nih.gov/7097924/ Percutaneous cementoplasty for pelvic bone metastasis (Marcy, 2000): https://pubmed.ncbi.nlm.nih.gov/11094996/ Safety and Efficacy of Sacroplasty for Sacral Fractures: A Systematic Review and Meta-Analysis (Chandra et al, 2019): https://pubmed.ncbi.nlm.nih.gov/31587952/ Percutaneous sacroplasty for osteoporotic sacral insufficiency fractures: a prospective, multicenter, observational pilot study (Frey et al, 2008): https://pubmed.ncbi.nlm.nih.gov/17981097/ Sacroplasty: A Ten-Year Analysis of Prospective Patients Treated with Percutaneous Sacroplasty: Literature Review and Technical Considerations (Frey et al, 2017): https://pubmed.ncbi.nlm.nih.gov/29149151/ Vertebral Augmentation: The Comprehensive Guide to Vertebroplasty, Kyphoplasty, and Implant Augmentation (Beall, 2020): https://www.thieme-connect.de/products/ebooks/book/10.1055/b000000226 An Interim Analysis of the First 102 Patients Treated in the Prospective Vertebral Augmentation Sacroplasty Fracture Registry (Beall et al, 2023): https://pubmed.ncbi.nlm.nih.gov/37207812/ Clinical Effect of Balloon Kyphoplasty in Elderly Patients with Multiple Osteoporotic Vertebral Fracture (Liu et al, 2019): ​https://journals.lww.com/njcp/fulltext/2019/22030/clinical_effect_of_balloon_kyphoplasty_in_elderly.1.aspx

In this episode of the BackTable MSK Podcast, Dr. Jacob Fleming and Dr. Douglas Beall discuss the challenges and advancements in treating sacral insufficiency fractures (SIF), the importance of real-world data in evaluating treatment efficacy, and the need to increase awareness of sacral fractures and sacroplasty. --- CHECK OUT OUR SPONSOR Stryker Interventional Spine https://www.strykerivs.com --- SYNPOSIS Dr. Beall emphasizes the underrecognition and undertreatment of sacral insufficiency fractures, pointing out the high mortality and chronic pain rates associated with non-treatment. He urges providers to consider this diagnosis, especially if the patient is describing symptoms of pain with position changes with standing, sitting, and laying, has pubic rami fractures, or reports a history of pelvic radiation. Even with imaging, the diagnosis can remain elusive, since it is not commonly recognized on x-ray and may not show obvious cortical disruption on CT or MRI. We also review the current literature on sacroplasty efficacy in lowering patient-reported pain scores and adverse events associated with treatment versus conservative management. Dr. Beall speaks about the importance of real-world data collection in the form of patient registries and the insight that these resulting studies have on applications of sacroplasty in specific patient populations. --- TIMESTAMPS 00:00 - Introduction 03:01 - Sacral Fractures and Sacroplasty 15:17 - Treatment Options for Sacral Fractures 17:34 - Consequences of Untreated Sacral Fractures 28:32 - Sacroplasty Registry and Current Research 38:08 - Imaging Modalities: CT vs. Fluoroscopy 40:49 - Complications of Sacroplasty: Extravasation 43:21 - Bone Quality and Fracture Healing 45:42 - Growing Awareness of Sacral Fractures and Treatment Options --- RESOURCES Spontaneous osteoporotic fracture of the sacrum. An unrecognized syndrome of the elderly (Lourie, 1982): https://pubmed.ncbi.nlm.nih.gov/7097924/ Percutaneous cementoplasty for pelvic bone metastasis (Marcy, 2000): https://pubmed.ncbi.nlm.nih.gov/11094996/ Safety and Efficacy of Sacroplasty for Sacral Fractures: A Systematic Review and Meta-Analysis (Chandra et al, 2019): https://pubmed.ncbi.nlm.nih.gov/31587952/ Percutaneous sacroplasty for osteoporotic sacral insufficiency fractures: a prospective, multicenter, observational pilot study (Frey et al, 2008): https://pubmed.ncbi.nlm.nih.gov/17981097/ Sacroplasty: A Ten-Year Analysis of Prospective Patients Treated with Percutaneous Sacroplasty: Literature Review and Technical Considerations (Frey et al, 2017): https://pubmed.ncbi.nlm.nih.gov/29149151/ Vertebral Augmentation: The Comprehensive Guide to Vertebroplasty, Kyphoplasty, and Implant Augmentation (Beall, 2020): https://www.thieme-connect.de/products/ebooks/book/10.1055/b000000226 An Interim Analysis of the First 102 Patients Treated in the Prospective Vertebral Augmentation Sacroplasty Fracture Registry (Beall et al, 2023): https://pubmed.ncbi.nlm.nih.gov/37207812/ Clinical Effect of Balloon Kyphoplasty in Elderly Patients with Multiple Osteoporotic Vertebral Fracture (Liu et al, 2019): ​https://journals.lww.com/njcp/fulltext/2019/22030/clinical_effect_of_balloon_kyphoplasty_in_elderly.1.aspx

1. PEMF treatment for ACDF. 2. Patient outcomes with Spinal Epidural Abscess. 3. Opioid Free Management with Anterior Cervical Surgery. 4. Early Mobilization of Elderly Patients after Lumbar Spinal Fusion

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: David P. Hudesman, MD There's been an increase in the elderly irritable bowel disease (IBD) population, and it's estimated that a third of our overall IBD population will soon be over the age of 60. When managing and diagnosing these patients, there's different factors to consider, like polypharmacy, biological versus chronological age, how fit these patients are versus how frail they are, and more. To take a deep dive into how IBD is affecting elderly patients, join Dr. Peter Buch as he speaks with Dr. David Hudesman, Professor of Medicine and Co-director of NYU Langone's Inflammatory Bowel Disease Center.

After the bumper double paper review episode, we fit two months of blog content into one episode. Iain and Simon discuss the management of the patient with chronic liver disease who has an acute decompensation, global health connections, whether mechanical CPR is more effective than human CPR and the potential effects on elderly patients staying in the ED overnight. References Conor Crowley, Justin Salciccioli, Wei Wang, Tomoyoshi Tamura, Edy Y. Kim, Ari Moskowitz, The association between mechanical CPR and outcomes from in-hospital cardiac arrest: An observational cohort study, Resuscitation, 2024, 110142, ISSN 0300-9572, https://doi.org/10.1016/j.resuscitation.2024.110142. Roussel M, Teissandier D, Yordanov Y, Balen F, Noizet M, Tazarourte K, Bloom B, Catoire P, Berard L, Cachanado M, Simon T, Laribi S, Freund Y; FHU IMPEC-IRU SFMU Collaborators; FHU IMPEC−IRU SFMU Collaborators. Overnight Stay in the Emergency Department and Mortality in Older Patients. JAMA Intern Med. 2023 Dec 1;183(12):1378-1385. doi: 10.1001/jamainternmed.2023.5961. PMID: 37930696; PMCID: PMC10628833. Recommended Conferences Premier Conference - 11th-12th June 2024, Winchester Tactical Trauma 24 - 7th-9th October, Sundsvall, Sweden RCEM Annual Scientific Conference

Who fact checks the fact checkers? Attorney Tom Renz refutes a recent AP “fact check” and alleges that the real “disinformation” is calling COVID mRNA shots “vaccines” instead of “gene therapy” – and says the FDA itself admits this in documents from 2020. Sasha Latypova – a former pharmaceutical executive – returns to discuss why Dr. Drew continues to vaccinate elderly patients despite warning against mRNA use for younger people, resisting vaccine mandates, and fighting against lockdowns. Tom Renz is an attorney from Ohio conducting ‘Lawfare for Freedom' by fighting corruption surrounding the COVID-19 pandemic at state and federal levels. Find out more at https://renz-law.com and follow him at https://x.com/RenzTom Sasha Latypova is a former pharmaceutical R&D executive with over 25 years of experience in clinical trials, clinical technologies, and regulatory approvals. She owned and managed several contract research organizations and worked for more than 60 pharma companies worldwide. She interacted with the FDA as part of a scientific industry consortium on improving cardiac safety assessments in clinical trials. Follow her at https://x.com/sasha_latypova and read more at https://sashalatypova.substack.com 「 SUPPORT OUR SPONSORS 」 Find out more about the brands that make this show possible and get special discounts on Dr. Drew's favorite products at https://drdrew.com/sponsors  • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at https://drdrew.com/paleovalley • COZY EARTH - Susan and Drew love Cozy Earth's sheets & clothing made with super-soft viscose from bamboo! Use code DREW to save up to 40% at https://drdrew.com/cozy • TRU NIAGEN - For almost a decade, Dr. Drew has been taking a healthy-aging supplement called Tru Niagen, which uses a patented form of Nicotinamide Riboside to boost NAD levels. Use code DREW for 20% off at https://drdrew.com/truniagen • GENUCEL - Using a proprietary base formulated by a pharmacist, Genucel has created skincare that can dramatically improve the appearance of facial redness and under-eye puffiness. Get an extra discount with promo code DREW at https://genucel.com/drew • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at https://twc.health/drew 「 GEAR 」 • NANLITE - Dr. Drew upgraded his studio with Nanlite: the best lighting for film, TV, and live streaming podcasts. Bring your vision to life at https://drdrew.com/nanlite 「 MEDICAL NOTE 」 Portions of this program may examine countervailing views on important medical issues. Always consult your personal physician before making any decisions about your health. 「 ABOUT THE SHOW 」 Ask Dr. Drew is produced by Kaleb Nation (https://kalebnation.com) and Susan Pinsky (https://twitter.com/firstladyoflove). This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. 「 ABOUT DR. DREW 」 Dr. Drew is a board-certified physician with over 35 years of national radio, NYT bestselling books, and countless TV shows bearing his name. He's known for Celebrity Rehab (VH1), Teen Mom OG (MTV), The Masked Singer (FOX), multiple hit podcasts, and the iconic Loveline radio show. Dr. Drew Pinsky received his undergraduate degree from Amherst College and his M.D. from the University of Southern California, School of Medicine. Read more at https://drdrew.com/about Learn more about your ad choices. Visit megaphone.fm/adchoices

Our gastroenterology experts consider the patient's underlying comorbidities when making treatment decisions regarding anti-TNFs. They also evaluate the safety profile and risks, particularly for elderly patients This podcast series has been supported by Viatris, who were not involved in the creation of this content.

CME credits: 0.75 Valid until: 26-01-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-case-of-arthur-frank-how-do-we-manage-elderly-patients-with-atrial-fibrillation/17991/ Older patients with atrial fibrillation (AF) are challenging to treat due to concomitant increased risk for both stroke and bleeding and the presence of an increasing number of comorbidities. Data from clinical trials, meta-analyses, and real-world evidence support the relative merits of NOAC therapy compared with conventional anticoagulation in treating elderly patients with AF. This program focuses on the factors and considerations that can drive the choice of anticoagulation therapy for elderly patients with AF, such as comorbidities and associated medications, falling risk, and monitoring and treatment adherence, which may help clinicians optimize the care of their elderly patients with AF.

CME credits: 0.75 Valid until: 26-01-2025 Claim your CME credit at https://reachmd.com/programs/cme/what-anticoagulation-options-are-available-to-optimize-care-in-the-management-of-elderly-patients-with-atrial-fibrillation/17990/ Older patients with atrial fibrillation (AF) are challenging to treat due to concomitant increased risk for both stroke and bleeding and the presence of an increasing number of comorbidities. Data from clinical trials, meta-analyses, and real-world evidence support the relative merits of NOAC therapy compared with conventional anticoagulation in treating elderly patients with AF. This program focuses on the factors and considerations that can drive the choice of anticoagulation therapy for elderly patients with AF, such as comorbidities and associated medications, falling risk, and monitoring and treatment adherence, which may help clinicians optimize the care of their elderly patients with AF.

CME credits: 0.75 Valid until: 26-01-2025 Claim your CME credit at https://reachmd.com/programs/cme/how-do-i-improve-the-ability-to-screen-interpret-and-diagnose-elderly-patients-with-atrial-fibrillation/17989/ Older patients with atrial fibrillation (AF) are challenging to treat due to concomitant increased risk for both stroke and bleeding and the presence of an increasing number of comorbidities. Data from clinical trials, meta-analyses, and real-world evidence support the relative merits of NOAC therapy compared with conventional anticoagulation in treating elderly patients with AF. This program focuses on the factors and considerations that can drive the choice of anticoagulation therapy for elderly patients with AF, such as comorbidities and associated medications, falling risk, and monitoring and treatment adherence, which may help clinicians optimize the care of their elderly patients with AF.

Lung cancer is a significant global health issue, being the second most commonly diagnosed cancer and the leading cause of cancer-related death worldwide. Non-small-cell lung cancer (NSCLC) represents the majority of lung cancer cases and is often diagnosed at an advanced stage. Epidermal growth factor receptor (EGFR) mutations are more common in Asian NSCLC populations than in Western populations. Activating EGFR mutations, such as exon 19 deletions and L858R, are predictive of response to tyrosine kinase inhibitors (TKIs) and have revolutionized the treatment landscape for patients with EGFR-mutated NSCLC. However, most clinical trials tend to lack data for the elderly population, even though a significant proportion of lung cancer patients are aged 65 years and older. This underrepresentation of elderly patients in clinical trials limits our understanding of the effectiveness and safety of EGFR-TKIs in this specific population. In this new study, researchers Ling-Jen Hung, Ping-Chih Hsu, Cheng-Ta Yang, Chih-Hsi Scott Kuo, John Wen-Cheng Chang, Chen-Yang Huang, Ching-Fu Chang, and Chiao-En Wu from Chang Gung University and Taoyuan General Hospital conducted a multi-institute retrospective study to investigate the effectiveness and safety of afatinib, gefitinib, and erlotinib for treatment-naïve elderly patients with EGFR-mutated advanced NSCLC. On January 8, 2024, their research paper was published in Aging's Volume 16, Issue 1, entitled, “Effectiveness and safety of afatinib, gefitinib, and erlotinib for treatment-naïve elderly patients with epidermal growth factor receptor-mutated advanced non-small-cell lung cancer: a multi-institute retrospective study.” Full blog - https://aging-us.org/2024/01/efficacy-and-safety-of-egfr-tkis-for-elderly-patients-with-nsclc/ Paper DOI - https://doi.org/10.18632/aging.205395 Corresponding author - Chiao-En Wu - 8805017@cgmh.org.tw Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.205395 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, elderly patients, epidermal growth factor receptor, tyrosine kinase inhibitor, non-small-cell lung cancer, real-world evidence About Aging-US Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways. Please visit our website at https://www.Aging-US.com​​ and connect with us: SoundCloud - https://soundcloud.com/Aging-Us Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Media Contact 18009220957 MEDIA@IMPACTJOURNALS.COM

The biennial International Workshop on Chronic Lymphocytic LeukemiaTM (iwCLL 2023) was held recently in Boston, MA, and brought together experts who... The post iwCLL 2023: The role of continuous BTKis, approaching Richter's transformation & addressing the underrepresentation of elderly patients in trials appeared first on VJHemOnc.

Nat O'Connor, Policy Specialist with Age Action

I see patients in their 70s 80s and 90s that I don't run through a range of manual muscle testing for their pain. This is how I prefer to assess and treat. And it works very well.     https://richardhazel.podia.com    

Chairman of The Irish Society of Physicians in Geriatric Medicine, Des O'Neill.

It is our responsibility to ensure that elderly individuals receive continuous healthcare in the comfort of their own homes. In this episode, Jeffrey Kang, CEO of WellBe Senior Medical, explains how he and his team revolutionized how seniors receive care during the COVID-19 pandemic. Dr. Kang's Chinese upbringing fuels his deep respect for the elderly and his belief in providing in-home care for geriatrics, aiming to conduct most traditional clinic procedures there and offering personalized treatment to simplify their healthcare process and reduce costs. Tune in to the discussion and learn how to make healthcare easier and more accessible, starting today! Click this link to access the show notes, transcript, and resources: https://outcomesrocket.health/ 

In this week's episode, we discuss the findings from a phase 2 study of lenalinomide plus rituximab in elderly frail patients with DLBCL, learn more about platelet GP6-mediated neutrophil recruitment in early stages of acute lung injury, and discuss a newly identified isoform of the tyrosine kinase AXL, termed AXL3, in mantle cell lymphoma.

While the treatment landscape of both Hodgkin and non-Hodgkin lymphoma (HL; NHL) has improved in recent years, there are several... The post Classifying frailty and approaching elderly patients with lymphoma appeared first on VJHemOnc.

Commentary by Dr. Candice Silversides

Commentary by Dr Eue-Keun Choi

Summary  In this episode of the Physical Activity Researcher Podcast, host Dr. Olli Tikkanen discusses a 2022 study titled "Criterion Validity of Linear Accelerations Measured with Low-Sampling-Frequency Accelerometers during Overground Walking in Elderly Patients with Knee Osteoarthritis". Led by Arash Ghaffari and his team from Aalborg University Hospital and Aalborg University in Denmark, this research investigates the reliability and validity of Fibion SENS, a low-sampling-frequency accelerometer, for monitoring the gait accelerations of patients with knee osteoarthritis. For the details of the research paper, please visit here. Timestamps: [00:00:00] Introduction [00:01:00] Setting the scene for the research [00:02:00] Overview of the study and research methods [00:03:00] Detailed discussion of the results [00:04:00] Limitations and considerations of Fibion SENS [00:05:00] Conclusions and potential impact of the study [00:06:00] Closing remarks If you are planning to conduct research or measurements related to sedentary behavior or physical activity, book a video call with Dr. Miriam Cabrita here for more guidance.  

Commentary by Dr Christopher Cheung

Latest figures show more than a hundred and thirty mainly elderly people are stuck in hospital because they can't get into a rest home. Chronic staff shortages in the aged care sector means there aren't enough beds for those who need them and that in turn makes it more difficult for people who need operations to get into hospital. Ruth Hill reports.

Commentary by Dr. Valentin Fuster

In this episode, Nick talks about selling Heal, rising costs for chronic conditions, high performance in business, when to release a second product, mistakes while releasing a second product, when to stop working on a product, raising funds in the challenging market conditions, how to separate personal vs professional life, why are Indians so driven, and much more!

In this JCO Article Insights episode, Davide Soldato summarizes two articles from the January 10th, 2023 Journal of Clinical Oncology issue: “Low-Intensity Chemotherapy for Early Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE Trial” and “Inflammation and Clinical Decline After Adjuvant Chemotherapy: Results From the Hurria Older Patients Prospective Study .” Both articles report on clinical outcomes of elderly patients treated with chemotherapy for early-stage breast cancer. TRANSCRIPT Davide Soldato: Thank you for joining JCO Article Insights. I'm Davide Soldato. Today I will be providing summaries for two different articles focused on elderly patients treated for early-stage breast cancer. Both articles are reported from the Hurria Older Patients With Breast Cancer Study. This study is also known as the HOPE Study, and it was a multicenter, prospective, study of patients aged 65 years and older treated with current standard (Neo)adjuvant chemotherapy regimens for early-stage breast cancer. The study captured several detailed geriatric clinical and treatment data from 500 patients that were recruited between September 2011 and May 2017 in 16 sites across the United States. The first article is titled ‘Low-intensity Adjuvant Chemotherapy for Breast Cancer in Older Women'. In this article, Dr. Sedrak and colleagues used data from the HOPE Study to investigate the incidence of chemotherapy administration with low relative dose intensity, associated risk factors, and relationship with survival outcomes. Previous data already showed that the receipt of chemotherapy with a low relative dose intensity is associated with inferior survival outcomes, and the commonly used threshold to define a low relative dose intensity is 85%. And this same threshold was used inside of the study that I am reporting. Elderly patients that are treated with chemotherapy are at higher risk of receiving chemotherapy with low relative dose intensity because of toxicity. However, previous data on the topic was mainly retrospective in nature and reported heterogeneous rates of low relative dose intensity up to 75%. And also, little information was available on risk factors and on the impact on survival outcomes. So, considering the paucity and the quality of the previous data and the potential clinical implication for survival outcomes, results of the HOPE Study are extremely relevant to clinical practice as they provide novel insight on the topic from a prospective multicenter study. In the analysis that was reported in the January issue of JCO, the authors excluded patients with HER-2 positive disease, those receiving nonstandard chemotherapy regimens, and those with upfront chemotherapy dose reduction. The final analytic cohort included 322 patients with a median age of 70 years, 44% with stage II, and 22% with stage III disease. Docetaxel and cyclophosphamide, and anthracycline-based chemotherapy, and this one, either alone or with subsequent paclitaxel, were the most commonly used chemotherapy regimens. Additionally, 85% of patients received a primary prophylaxis with G-CSF. Relative dose intensity was variable in the study. More than half of the patients received full course chemotherapy with 100% relative dose intensity. However, the incidence of low relative dose intensity in the HOPE study was still 21%, thus identifying a subset of patients who received chemotherapy with a suboptimal dose intensity. The rates of low relative dose intensity were higher for patients receiving either anthracycline-based chemotherapy and those with a planned treatment duration over 12 weeks. The authors developed a multivariable logistic regression model with stepwise selection to identify risk factors associated with low relative dose intensity. The results of this analysis showed that an age higher than 76 years, administration of anthracycline and CMF-based regimens, and a physician-rated Karnofsky Performance Status under 90 were associated with higher risk of low relative dose intensity ranging from 3 to 5 times greater compared to reference categories. Then the authors realized another model where they used the previously mentioned three variables, but they also adjusted for relevant clinical characteristics, including age, stage, liver and renal function, and also previous cardiovascular disease. And in this model, the three variables that were observed previously— age, type of chemotherapy, and Karnofsky Performance Status—remained significantly associated with higher risk of receiving chemotherapy with a low relative dose intensity. Finally, the Authors evaluated the association between a low relative dose intensity and survival outcomes, specifically breast cancer-specific mortality, non-breast cancer-specific mortality, and overall survival. Patients who received the chemotherapy with a low relative dose intensity had a significantly lower overall survival, and this association persisted even after excluding patients older than 76 years. A higher risk of both breast cancer and non-breast cancer mortality was observed in patients with low relative dose intensity chemotherapy. However, the number of cause-specific events was too low to obtain statistical significance for both these endpoints. In conclusion, the study by Dr. Sedrak and colleagues provides several relevant information for clinical practice. First, the HOPE study demonstrates that the administration of chemotherapy to elderly patients while maintaining an appropriate relative dose intensity is feasible. However, 1 in 5 patients received chemotherapy with a low relative dose intensity. So the results of this study reinforced the need to identify upfront patients most likely to require dose reduction. And these patients should be proactively supported during the administration of chemotherapy to ensure that appropriate toxicity management can reduce the risk of low relative dose intensity. Second, in the study, the authors observed a significant association between a low relative dose intensity and the CARG and CARG-BC scores. These scores were previously validated to predict chemotherapy toxicity. The presence of this association is important because it suggests that these validated scores can be used routinely in clinical practice to identify patients that might benefit from a comprehensive geriatric assessment to optimize comorbidities treatments and assure optimal delivery of chemotherapy. Finally, longer follow-up will provide the opportunity to establish if the higher mortality that was observed in the HOPE study in patients receiving chemotherapy with a low relative dose intensity is consequent to the low chemotherapy efficacy or to a clinical decline that might be consequent to chemotherapy itself. I will now move to the second article titled ‘Inflammation and Clinical Decline After Adjuvant Chemotherapy in Older Adults With Breast Cancer'. This article was published by Dr. Ji and colleagues, and it describes a secondary analysis of the HOPE study. In this specific manuscript, the authors wanted to evaluate the potential predictive role of baseline inflammatory biomarkers on the risk of clinical decline after administration of chemotherapy. In the HOPE study, the authors collected information on frailty stages, pre and post-chemotherapy using the Deficit-Accumulation Index (DAI): this is a 50-item scale that evaluates deficits in physical activity of daily living, instrumental activities of daily living, psychosocial status, nutrition, frequency of falls, number of medications, comorbid conditions, social support, and laboratory values. The inflammatory biomarkers that were evaluated in the current study were CRP and IL-6, and their levels were determined on pre-chemotherapy blood specimens. Using the deficit accumulation index score, patients were categorized pre-chemotherapy as being robust, pre-frail, or frail; this is important because previous studies already demonstrated that there is a significant association between this categorization and morbidity and mortality outcomes in older adults. The primary outcome of the study was a chemotherapy-induced clinical decline that was defined as a decline from a robust stage pre-chemotherapy to a pre-frail or frail status after chemotherapy. The overall analytic cohorts included 295 robust women. The median age was 69, 62% of patients had stage II or III disease, median number of comorbidities was 1.9, and mean BMI was 28.5. One in 4 older women included in the study experienced a chemotherapy-induced decline in frailty status, so this means that they transitioned from a robust status pre-chemotherapy to a pre-frail or frail status after chemotherapy. This decline in frailty status was more frequent among patients with a higher BMI, those with more comorbidities, and those with stage II and III disease. Additionally, the patients who experienced chemotherapy-induced decline had higher baseline levels of both IL-6 and CRP. Univariate analysis also showed that patients with high IL-6 and CRP had a threefold higher risk of experiencing chemotherapy-induced decline in frailty stages. This association between higher inflammation and the decline in frailty status remained significant in a multivariable logistic regression analysis that was adjusted for relevant clinical and demographic characteristics, including age, stage, race, education, BMI, breast cancer surgery, anti-inflammatory medication, and number of comorbidities. Specifically, the results of these models showed that patients who had both high CRP and IL-6 at baseline had a threefold higher risk of experiencing a decline in frailty status. So, in conclusion, this study shows a significant association between systemic inflammation and a decline in frailty status in elderly patients receiving chemotherapy for early-stage breast cancer. From a biological perspective, these higher levels of systemic inflammation might be a direct byproduct of a more advanced biological aging following the accumulation of senescent cells. There are several intriguing future perspectives that come from this study. First, if validated in additional cohorts, these findings might lead to higher treatment personalization thanks to the identification of patients at risk of clinical decline based on clinical characteristics but also on systemic inflammation. And these patients could be then proactively supported during chemotherapy to try and reduce the appearance of the clinical decline. Second, we know that inflammation is a potentially targetable pathway, and previous data obtained in breast cancer patients showed the potential of behavioral, exercise, and dietary interventions in modulating systemic inflammation. So, based on this new information, if validated in additional cohorts, future research should then evaluate if this interventions can be used to treat and eventually prevent the decline in frailty status in patients with high baseline systemic inflammation before receiving chemotherapy. This is Davide Soldato in this episode of JCO Article Insights. We discussed two publications: ‘Low-intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results from the Prospective Multicenter HOPE Trial',  and the second one, ‘Inflammation and Clinical Decline After Adjuvant Chemotherapy in Older Adults with Breast cancer: Results from the Hurria Older Patients Prospective Study'. Thank you for your attention, and stay tuned for the next episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experience, and conclusions. Guests' statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    Like, share and subscribe so you never miss an episode and leave a rating or review. Articles Low-intensity Adjuvant Chemotherapy for Breast Cancer in Older Women Inflammation and Clinical Decline After Adjuvant Chemotherapy in Older Adults With Breast Cancer Find more articles from the January 10 issue.

Show notes at pharmacyjoe.com/episode785. In this episode, I’ll discuss the lowest effective dose of IV or IM haloperidol for elderly hospitalized patients with agitation. The post 785: Haloperidol for Agitation in Elderly Patients – How Low Can You Go? appeared first on Pharmacy Joe.

Show notes at pharmacyjoe.com/episode785. In this episode, I’ll discuss the lowest effective dose of IV or IM haloperidol for elderly hospitalized patients with agitation. The post 785: Haloperidol for Agitation in Elderly Patients – How Low Can You Go? appeared first on Pharmacy Joe.

We spoke with Jane Meadus, a lawyer at the Advocacy Centre for the Elderly, about long-term care advocates preparing a constitutional challenge to an Ontario law that allows some discharged elderly hospital patients to be forced into a nursing home they did not choose. Jane says this comes down to a broken system - the government doesn't have preventative measures, like home care, to keep elderly out of hospital. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of Quah (Q & A), Sal, Adam & Justin coach four Pump Heads via Zoom. Mind Pump Fit Tip: One of the BEST things you can do to increase the pump is to drink more WATER! (2:58) The benefits of red-light therapy to relieve pain. (10:39) One Twitch streamer wanted ALL the views! (13:27) Magnets are powerful! (21:14) The Seed impact. (28:07) The trends of drug use during the pandemic. (29:39) How spoiled are these kids now?! (31:53) #ListenerLive question #1 - Are there downsides to prolonged periods of resistance training while fasted? (41:57) #ListenerLive question #2 - Can doing excess cardio hinder my muscle growth and weight loss, and slow my metabolism more? (48:56) #ListenerLive question #3 - How do I fit MAPS Anabolic into my schedule as a firefighter? (1:02:01) #ListenerLive question #4 - What is the safest way to reduce my weight without having to lose too much muscle? (1:14:51) Related Links/Products Mentioned Ask a question to Mind Pump, live! Email: live@mindpumpmedia.com Visit Joovv for an exclusive offer for Mind Pump listeners! Visit Seed for an exclusive offer for Mind Pump listeners! **Promo code MINDPUMP at checkout for 15% off your first month's supply of Seed's DS-01™ Daily Synbiotic** September Promotion: Skinny Guy Bundle (MAPS ANABOLIC // MAPS AESTHETIC // NO B.S. 6-PACK FORMULA // INTUITIVE NUTRITION GUIDE // OCCLUSION TRAINING GUIDE.) HALF OFF!! Also, the Fit Mom Bundle (MAPS ANYWHERE // MAPS ANABOLIC // MAPS HIIT // and INTUITIVE NUTRITION GUIDE.) HALF OFF!! **Code SEPT50 at checkout** Visit Drink LMNT for an exclusive offer for Mind Pump listeners! Improvement of Pain and Disability in Elderly Patients with Degenerative Osteoarthritis of the Knee Treated with Narrow-Band Light Therapy The effects of laser treatment in tendinopathy: a systematic review Twitch streamer Kimmikka who was filmed having sex on live video banned from platform Mind Pump Store Visit MASSZYMES by biOptimizers for an exclusive offer for Mind Pump listeners! **Promo code MINDPUMP10 at checkout** Young Adults Used Pot and Psychedelics in Record Numbers Last Year, While Adolescent Drug Use Fell Sharply Amazon's ‘The Lord of the Rings' to Cost $465M for Just One Season Visit Organifi for the exclusive offer for Mind Pump listeners! **Promo code MINDPUMP at checkout** Mind Pump #1565: Why Women Should Bulk Mind Pump #1487: The Best Way For First Responders To Stay In Shape MAPS Suspension Training MAPS Fitness Performance MAPS Symmetry Mind Pump Podcast – YouTube Mind Pump Free Resources People Mentioned History in Memes (@historyinmemes) Instagram Ben Pakulski (@bpakfitness) Instagram Ben Patrick (@kneesovertoesguy) Instagram

In the latest episode of BCRF's official podcast, Investigating Breast Cancer, Dr. Hyman Muss explores the need for more research in the geriatric oncology field. Thanks to Dr. Muss and others, much has been learned about breast cancer in elderly people—but there's still much more to uncover. A BCRF investigator since 2000, Dr. Muss is professor of medicine at the University of North Carolina School of Medicine and director of the Geriatric Oncology Program at the UNC Lineberger Comprehensive Cancer Center.

Carmen Quatman, MD, PhD, is an orthopedic surgeon specializing in trauma care, with fellowship training in geriatric orthopedic trauma. In part one of a two part interview, she discusses important considerations for geriatric patients, to better help them be safe at home and have as high a quality of life as possible.